Expanded package to include new neurofilament light chain (NfL) analysis; Health Canada confirms March 2027 filing timelineSubmission would be PrimeC's first marketing application in any jurisdiction, potentially
Presentation will highlight how findings from the PARADIGM program are informing the clinical development strategy for PARAGONCAMBRIDGE, Mass., Oct. 29, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN)
Patent application seeks protection for PrimeC use in concussion, blast-related brain injury and chronic traumatic encephalopathy (CTE)Positions PrimeC for potential expansion beyond ALS into an indication affecting
Shares continue to trade on Nasdaq pending the Panel's decision; minimum bid price compliance already regainedNear-term catalysts include a New Drug Submission to Health Canada targeted for December 2026 and a
Company regains compliance with Nasdaq's minimum bid price requirement and intends to request a Nasdaq Hearings Panel hearing to seek additional time to regain compliance with the minimum market value
Management will participate in the 5th Annual ROTH Healthcare Opportunities Conference on September 29, 2026 and will be available for one-on-one investor meetings during the conferenceCAMBRIDGE, Mass., Sept. 28, 2026
CAMBRIDGE, Mass., Sept. 25, 2026 /PRNewswire/ -- Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing disease-modifying
Company presentation on Tuesday, September 15 at 4:30 p.m. ETManagement will be available for one-on-one investor meetings during the conferenceCAMBRIDGE, Mass., Sept. 10, 2026 /PRNewswire/ -- NeuroSense Therapeutics
Three-part program - AI-enabled characterization of PrimeC's formulation advantage, an active-comparator trial against edaravone, and a streamlined pivotal pathway - is designed to strengthen PrimeC's
CAMBRIDGE, Mass., Aug. 13, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for
Final meeting minutes reflect alignment with Health Canada on the planned content and structure of the ALS submissionCAMBRIDGE, Mass., Aug. 6, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN)
The planned submission follows alignment with Health Canada on the NDS pathway and is supported by additional PARADIGM data, including a survival benefit and consistent effects across PrimeC's multi-pathway
Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forwardCAMBRIDGE, Mass., July 6, 2026 /PRNewswire/ -- NeuroSense
First randomized, double-blind, placebo-controlled trial to demonstrate treatment-associated reduction of TDP-43 in people living with ALSTDP-43 pathology is present in more than 97% of ALS cases and is widely
PrimeC was associated with changes across multiple biomarkers spanning key neurodegenerative disease pathways, providing early biological evidence consistent with potential target engagementFindings support continued
